- AGC Biologics and BioConnection partner to provide end-to-end biopharmaceutical development and manufacturing.
- A seamless “gene to vial” service with a single contract and project management team is introduced.
AGC Biologics, a global biopharmaceutical CDMO, and BioConnection, a specialised contract manufacturing organisation (CMO), have announced a new partnership to provide comprehensive biopharmaceutical development and manufacturing services. This collaboration, effective from 22nd May 2024, aims to streamline drug substance and drug product production.
The partnership offers a full-service clinical-stage development and manufacturing solution, significantly accelerating timelines. By combining AGC Biologics’ development expertise with BioConnection’s aseptic filling capabilities, the companies can now provide a “gene to vial” service under a single contract and project management team. This integration allows developers to save time and resources, avoiding the complexity of negotiating separate contracts.
“Now more than ever, global pharmaceutical companies and developers need reliable facilities to produce and fill their drug products. By combining our resources with BioConnection, we are offering a new end-to-end solution under one contract with AGC Biologics,” said Patricio Massera, CEO of AGC Biologics.
Alexander Willemse, CEO of BioConnection, added, “We are excited to join forces with AGC Biologics to offer integrated manufacturing solutions that address the complexities of biopharmaceutical development. Together, we are well-positioned to support our clients at every stage.”
 Overview of outsourcing trends 
